Executive Director; Ionis Pharmaceuticals
Dr. Holly Kordasiewicz is an Executive Director in the Neuroscience Drug Discovery and Biomarker Departments at Ionis Pharmaceuticals, a company that specializes in RNA therapeutics. Holly heads a team focused on identifying antisense oligonucleotide therapeutics for neurodegenerative diseases, including drugs now in clinical trials for ALS, Alzheimer’s disease, and Huntington’s disease. Holly also heads the biomarker team, developing biomarkers to support preclinical and clinical studies for systemic and centrally delivered antisense drugs. Holly joined Ionis 7 years ago after working on the preclinical validation for Ionis’ Huntington’s disease program as a post-doctoral fellow in the laboratory of Dr. Don Cleveland at UCSD. Holly began her work on dominantly inherited polyglutamine diseases at the University of Minnesota, where she received her Ph.D. in Neuroscience.